Form 4: TNON awards 128,957 RSUs to director; two vesting dates

Rhea-AI Filing Summary

Tenon Medical (TNON) filed a Form 4 reporting that Director Richard Ferrari received 128,957 restricted stock units (RSUs) on October 13, 2025. Each RSU represents a right to receive one share of common stock. The award vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The filing lists the transaction at $0 per unit and shows direct ownership of the RSUs following the grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ferrari Richard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	128,957	$0.00	--

Holdings After Transaction: Restricted Stock Units — 128,957 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Ferrari Richard

(Last) (First) (Middle)

104 COOPER COURT

(Street)

LOS GATOS CA 95032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/13/2025		A		128,957		(2)	(2)	Common Stock	128,957	$0	128,957	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

	/s/ Richard Ferrari	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tenon Medical (TNON) report in this Form 4?

A grant of 128,957 RSUs to Director Richard Ferrari on 10/13/2025.

How do the RSUs for TNON’s director vest?

They vest 50% on 01/01/2026 and 50% on 07/31/2026.

What does each RSU represent for TNON?

Each RSU represents a contingent right to receive one share of common stock.

What price is shown for the RSU transaction?

The filing lists a price of $0 per RSU.

What is the ownership form of these RSUs?

The RSUs are reported under direct ownership following the grant.

Who is the reporting person in TNON’s Form 4?

Director Richard Ferrari.